Home > Resources > Whitepapers > WILL PHARMA COMMIT TO DELIVERING AFFORDABLE THERAPEUTICS AGAINST COVID-19?

WILL PHARMA COMMIT TO DELIVERING AFFORDABLE THERAPEUTICS AGAINST COVID-19?

April 8, 2020

EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

Pavilion Health Australia Pty Ltd.

The Pavilion Health group of companies offers an unprecedented depth of ability and experience to the health industry. As an Australian based organisation, our experience is well-founded in ICD-10-AM (International Classification of Diseases, 10th Revision, Australian Modified), ACHI (Australian Classification of Health Interventions), AR-DRG (Australian Refined Diagnosis Related Groups), and ACS (Australian Coding Standards).

OTHER WHITEPAPERS
news image

How Specialty Pharmacy Can Drive Better Outcomesin Multiple Sclerosis

whitePaper | June 14, 2022

Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system. Characterized by demyelination and neurodegeneration that affects the communication between the brain and other parts of the body, MS leads to physical and cognitive disability.

Read More
news image

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO) to support the conversion.

Read More
news image

Manufacturing High-Quality Capsule Products for Pharmaceutical and Nutraceutical Applications

whitePaper | October 25, 2022

To confirm the suitability of empty hard capsules for use in the application of quality-by-design (QbD) in the development and manufacturing of finished pharmaceutical products, the quality target product profile (QTPP) defined by eight critical quality attributes (CQA’s) was examined.

Read More
news image

Essential for Stable U.S. Supply Chains of Quality Pharmaceuticals

whitePaper | May 11, 2022

CDER is taking another step towards realizing the vision for pharmaceutical quality in the 21st century: a maximally efficient, agile, flexible manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight.

Read More
news image

Deal-Making Roundup

whitePaper | November 19, 2022

In the second year of the pandemic, dealmaking continued to take place at record levels, maintaining much of the momentum created during 2020.

Read More
news image

Blockchain technology in the pharmaceutical industry

whitePaper | March 11, 2022

Blockchain technology is accelerating digital transformation across multiple industries, including the pharmaceutical industry.

Read More

How Specialty Pharmacy Can Drive Better Outcomesin Multiple Sclerosis

whitePaper | June 14, 2022

Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system. Characterized by demyelination and neurodegeneration that affects the communication between the brain and other parts of the body, MS leads to physical and cognitive disability.

Read More

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO) to support the conversion.

Read More

Manufacturing High-Quality Capsule Products for Pharmaceutical and Nutraceutical Applications

whitePaper | October 25, 2022

To confirm the suitability of empty hard capsules for use in the application of quality-by-design (QbD) in the development and manufacturing of finished pharmaceutical products, the quality target product profile (QTPP) defined by eight critical quality attributes (CQA’s) was examined.

Read More

Essential for Stable U.S. Supply Chains of Quality Pharmaceuticals

whitePaper | May 11, 2022

CDER is taking another step towards realizing the vision for pharmaceutical quality in the 21st century: a maximally efficient, agile, flexible manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight.

Read More

Deal-Making Roundup

whitePaper | November 19, 2022

In the second year of the pandemic, dealmaking continued to take place at record levels, maintaining much of the momentum created during 2020.

Read More

Blockchain technology in the pharmaceutical industry

whitePaper | March 11, 2022

Blockchain technology is accelerating digital transformation across multiple industries, including the pharmaceutical industry.

Read More
More Whitepapers

Spotlight

Pavilion Health Australia Pty Ltd.

The Pavilion Health group of companies offers an unprecedented depth of ability and experience to the health industry. As an Australian based organisation, our experience is well-founded in ICD-10-AM (International Classification of Diseases, 10th Revision, Australian Modified), ACHI (Australian Classification of Health Interventions), AR-DRG (Australian Refined Diagnosis Related Groups), and ACS (Australian Coding Standards).

Events